Literature DB >> 31405959

Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.

Greg Harris1, Bruce E Holbein2,3, Hongyan Zhou1, H Howard Xu4, Wangxue Chen5,6.   

Abstract

Porcine mucin has been commonly used to enhance the infectivity of bacterial pathogens, including Acinetobacter baumannii, in animal models, but the mechanisms for enhancement by mucin remain relatively unknown. In this study, using the mouse model of intraperitoneal (i.p.) mucin-enhanced A. baumannii infection, we characterized the kinetics of bacterial replication and dissemination and the host innate immune responses, as well as their potential contribution to mucin-enhanced bacterial virulence. We found that mucin, either admixed with or separately injected with the challenge bacterial inoculum, was able to enhance the tissue and blood burdens of A. baumannii strains of different virulence. Intraperitoneal injection of A. baumannii-mucin or mucin alone induced a significant but comparable reduction of peritoneal macrophages and lymphocytes, accompanied by a significant neutrophil recruitment and early interleukin-10 (IL-10) responses, suggesting that the resulting inflammatory cellular and cytokine responses were largely induced by the mucin. Depletion of peritoneal macrophages or neutralization of endogenous IL-10 activities showed no effect on the mucin-enhanced infectivity. However, pretreatment of mucin with iron chelator DIBI, but not deferoxamine, partially abolished its virulence enhancement ability, and replacement of mucin with iron significantly enhanced the bacterial burdens in the peritoneal cavity and lung. Taken together, our results favor the hypothesis that iron at least partially contributes to the mucin-enhanced infectivity of A. baumannii in this model. © Crown copyright 2019.

Entities:  

Keywords:  Acinetobacter; intraperitoneal infection; porcine mucin; virulence

Mesh:

Substances:

Year:  2019        PMID: 31405959      PMCID: PMC6803341          DOI: 10.1128/IAI.00591-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  MUCIN AS A RESISTANCE-LOWERING SUBSTANCE.

Authors:  L Olitzki
Journal:  Bacteriol Rev       Date:  1948-06

2.  Porcine Gastric Mucin Triggers Toxin Production of Enteropathogenic Bacillus cereus.

Authors:  Nadja Jessberger; Richard Dietrich; Ann-Katrin Mohr; Claudia Da Riol; Erwin Märtlbauer
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

3.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

4.  Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia.

Authors:  Gerald L Murray; Kirill Tsyganov; Xenia P Kostoulias; Dieter M Bulach; David Powell; Darren J Creek; John D Boyce; Ian T Paulsen; Anton Y Peleg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

5.  High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils.

Authors:  Hongyu Qiu; Rhonda KuoLee; Greg Harris; Wangxue Chen
Journal:  Microbes Infect       Date:  2009-06-30       Impact factor: 2.700

6.  A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain.

Authors:  Greg Harris; Rhonda Kuo Lee; Christopher K Lam; Gregory Kanzaki; Girishchandra B Patel; H Howard Xu; Wangxue Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

7.  In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus.

Authors:  Y Obana; T Nishino; T Tanino
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

8.  Iron-controlled infection with Neisseria meningitidis in mice.

Authors:  B E Holbein
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

9.  DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity.

Authors:  M Trisha C Ang; Roger Gumbau-Brisa; David S Allan; Robert McDonald; Michael J Ferguson; Bruce E Holbein; Matthias Bierenstiel
Journal:  Medchemcomm       Date:  2018-06-18       Impact factor: 3.597

10.  Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for Carbapenem-Resistant Gram-Negative Bacteria.

Authors:  Jung Yeon Park; Chulmin Park; Hye Sun Chun; Ji Hyun Byun; Sung Yeon Cho; Dong Gun Lee
Journal:  Infect Chemother       Date:  2017-03-06
View more
  4 in total

1.  A conserved region of Acinetobacter trimeric autotransporter adhesion, Ata, provokes suppression of Acinetobacter baumannii virulence.

Authors:  Ramin Hatefi Oskuei; Shakiba Darvish Alipour Astaneh; Iraj Rasooli
Journal:  Arch Microbiol       Date:  2021-04-27       Impact factor: 2.552

2.  Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study.

Authors:  Fernando L Gordillo Altamirano; Xenia Kostoulias; Dinesh Subedi; Denis Korneev; Anton Y Peleg; Jeremy J Barr
Journal:  EBioMedicine       Date:  2022-05-07       Impact factor: 11.205

Review 3.  Host Innate Immune Responses to Acinetobacter baumannii Infection.

Authors:  Wangxue Chen
Journal:  Front Cell Infect Microbiol       Date:  2020-09-14       Impact factor: 5.293

4.  DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model.

Authors:  Levi A Tamming; Diana Duque; Anh Tran; Wanyue Zhang; Annabelle Pfeifle; Emmanuel Laryea; Jianguo Wu; Sathya N Thulasi Raman; Caroline Gravel; Marsha S Russell; Anwar M Hashem; Reem M Alsulaiman; Rowa Y Alhabbab; Jun Gao; David Safronetz; Jingxin Cao; Lisheng Wang; Wangxue Chen; Michael J W Johnston; Simon Sauve; Michael Rosu-Myles; Xuguang Li
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.